Galena reports today after the close


Controversial biotech Galena Biopharma (GALE) will report Q4 and 2013 results after today's close.

Consensus estimates for the quarter are a loss of $0.09/share on revenues of $1.6M. Estimates for the year are a loss of $0.41/share on revenues of $2.7M.

Consensus views for 2014 are a loss of $0.36/share on revenues of $12.6M.

96 mutual funds have positions, up from 27 a year earlier.

Shares are up 7% premarket.

From other sites
Comments (3)
  • GlennLangohr
    , contributor
    Comments (139) | Send Message
     
    Galena should have good numbers with Abstral market share. Hopefully strong guidance and as reasonable explanation of the publicity scandal as possible.
    17 Mar 2014, 12:14 PM Reply Like
  • parvin
    , contributor
    Comments (2) | Send Message
     
    Does anyone have confirmation of the earnings release and conference call? Please post the phone number if you have one.
    17 Mar 2014, 01:42 PM Reply Like
  • User 8154791
    , contributor
    Comments (5) | Send Message
     
    Apparently no conference call today.
    17 Mar 2014, 05:14 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs